CXCL11 and head and neck squamous cell carcinoma: Further comprehensive investigations on larger patient cohorts in correlation with the specific individual therapy regimen, therapy response, and patient survival are required to elucidate the meaningfulness of peripheral blood monocyte subsets and chemokine CXCL11 as potential bioliquid indicators in HNSCC.